Elanco Animal Health (ELAN) Reports In-Line Q4 EPS; Confirms Guidance

Elanco Animal Health (NYSE: ELAN) reported Q4 EPS of $0.23, in-line with the analyst estimate of $0.23. Revenue for the quarter came in at $787 million versus the consensus estimate of $791.5 million.

GUIDANCE:

Confirmed financial guidance for the full year 2020, with total revenue in the range of $3.05 billion - $3.11 billion, Core Revenue in the range of $3.00 billion - $3.06 billion, and EPS in the range of $0.04 - $0.16 (reported), or $1.09 to $1.16 (adjusted). Guidance does not contemplate contributions from Bayer animal health or additional financing elements.

For earnings history and earnings-related data on Elanco Animal Health (ELAN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Bernstein SocGen Group Upgrades X-Fab Silicon Foundries SE (XFAB:FP) to Outperform
• MP Materials seen largely insulated after China export-control move